Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Accumulated Expenses (2016 - 2019)

Neurocrine Biosciences (NBIX) has disclosed Accumulated Expenses for 8 consecutive years, with $24.9 million as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Accumulated Expenses rose 160.5% year-over-year to $24.9 million, compared with a TTM value of $24.9 million through Dec 2017, up 160.5%, and an annual FY2017 reading of $24.9 million, up 160.5% over the prior year.
  • Accumulated Expenses was $24.9 million for Q4 2017 at Neurocrine Biosciences, up from $18.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $24.9 million in Q4 2017 and bottomed at $6.1 million in Q1 2014.
  • Average Accumulated Expenses over 5 years is $12.0 million, with a median of $9.4 million recorded in 2014.
  • The sharpest move saw Accumulated Expenses fell 18.04% in 2014, then skyrocketed 160.5% in 2017.
  • Year by year, Accumulated Expenses stood at $8.0 million in 2013, then dropped by 18.04% to $6.5 million in 2014, then grew by 12.85% to $7.4 million in 2015, then grew by 29.91% to $9.6 million in 2016, then surged by 160.5% to $24.9 million in 2017.
  • Business Quant data shows Accumulated Expenses for NBIX at $24.9 million in Q4 2017, $18.4 million in Q1 2017, and $9.6 million in Q4 2016.